Incorporation of liver chemistry score in predicting survival of liver-involved advanced gastric cancer patients who received palliative chemotherapy

被引:4
|
作者
Feng, Ying [1 ]
Zhang, Cheng [1 ,2 ]
Wu, Zhijun [3 ]
Xu, Hui [1 ,2 ]
Zhang, Xiaopeng [4 ]
Feng, Chong [4 ]
Shao, Jingyi [1 ]
Xie, Minmin [1 ]
Yang, Yahui [1 ]
Zhang, Yi [1 ]
Ma, Tai [1 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China
[2] Anhui Prov Canc Inst, Anhui Prov Off Canc Prevent & Control, Hefei, Peoples R China
[3] Maanshan Municipal Peoples Hosp, Dept Oncol, Maanshan, Peoples R China
[4] Hefei Ctr Dis Control & Prevent, Dept Noncommunicable Dis & Hlth Educ, Hefei, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 03期
关键词
gastric cancer; liver function tests; liver metastasis; survival analysis; PHASE-III; PROGNOSTIC-FACTORS; FUNCTION TESTS; CISPLATIN; TRIAL; MODEL; MULTICENTER; S-1;
D O I
10.1002/cam4.5179
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Gastric cancer liver metastasis (GCLM) patients usually accompany by abnormal serum liver function tests (LFTs) more or less; however, the prognostic value of LFTs is not fully understood. This study aimed to develop a liver chemistry score (LCS) based on LFTs and incorporate it into prognosis determination for GCLM patients who received palliative chemotherapy. Methods Data were derived from hospitalized GCLM patients in two general hospitals in China. LCS was generated based on the results of LFTs by LASSO regression. Cutoff value of the score was determined by restricted cubic spline. The score was then incorporated into Cox regression analysis to construct a predictive nomogram; the model was then evaluated internally and externally by AUC of time-dependent receiver operating characteristic curves (ROC) and calibration curves. Results Three hundred and thirty-six and 72 patients were included in development and validation cohort, respectively. LASSO regression analysis in development cohort finally reached a two-parametric LCS calculated on AST and ALP levels as 0.03343515 x ln (AST, U/L) + 0.02687997 x ln (ALP, U/L), and 0.232 was set as optimal cutoff value. Patients in low (LCS < 0.232) or high (LCS >= 0.232) score group experienced different survival times; median OS was 13.54 (95% CI: 11.1-15.6) months in the low LCS group and 7.3 (6.6-9.3) months in the high LCS group (p < 0.001). A nomogram including LCS and other clinical parameters was constructed and showed superior performance than model not including LCS. AUC of 6-month ROC improved from 0.647 (95% CI: 0.584-0.711) to 0.699 (0.638-0.759) in internal validation, and 0.837 (0.734-0.940) to 0.875 (0.784-0.966) in external validation. Conclusions Liver chemistry score is useful in determining the prognosis of gastric cancer patients with liver metastasis and may be helpful to clinicians in decision-making.
引用
收藏
页码:2831 / 2841
页数:11
相关论文
共 50 条
  • [21] Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer
    Ekstrom, Anders
    Brun, Eva
    Eberhard, Jakob
    Segerlantz, Mikael
    ACTA ONCOLOGICA, 2021, 60 (12) : 1580 - 1588
  • [22] Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study
    Ishida, Hiroo
    Sunakawa, Yu
    Kodera, Yasuhiro
    Yoshida, Kazuhiro
    Kochi, Mitsugu
    Kakeji, Yoshihiro
    Sano, Takeshi
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    EUROPEAN JOURNAL OF CANCER, 2025, 219
  • [23] Experience of gastric cancer in a patient who had received a living-donor liver transplantation
    Nagata, Yasuhiro
    Eguchi, Susumu
    Takatsuki, Mitsuhisa
    Enjoji, Akihito
    Ichikawa, Tatsuki
    Hayashi, Tomayoshi
    Kanematsu, Takashi
    GASTRIC CANCER, 2007, 10 (03) : 187 - 190
  • [24] Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy
    Wang, Jin
    Yang, Bowen
    Li, Zhi
    Qu, Jinglei
    Liu, Jing
    Song, Na
    Chen, Ying
    Cheng, Yu
    Zhang, Simeng
    Wang, Zhongqing
    Qu, Xiujuan
    Liu, Yunpeng
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [25] Experience of gastric cancer in a patient who had received a living-donor liver transplantation
    Yasuhiro Nagata
    Susumu Eguchi
    Mitsuhisa Takatsuki
    Akihito Enjoji
    Tatsuki Ichikawa
    Tomayoshi Hayashi
    Takashi Kanematsu
    Gastric Cancer, 2007, 10 : 187 - 190
  • [26] Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB
    Hochfelder, Colleen G.
    Mehta, Vikas
    Kabarriti, Rafi
    McGinn, Aileen P.
    Castellucci, Enrico
    Ow, Thomas J.
    ORAL ONCOLOGY, 2021, 121
  • [27] Combined with prognostic nutritional index and IgM for predicting the clinical outcomes of gastric cancer patients who received surgery
    Du, Zhongze
    Sun, Hao
    Zhao, Ruihu
    Deng, Guiming
    Pan, Hongming
    Zuo, Yanjiao
    Huang, Rong
    Xue, Yingwei
    Song, Hongjiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
    Hu, Qing
    Wang, Jian
    Xu, Wei-Guo
    Shao, Peng
    Li, Gang
    PRECISION MEDICAL SCIENCES, 2021, 10 (02): : 78 - 82
  • [29] Prognostic factors in patients who received paraaortic lymph node dissection for locally advanced gastric cancer with extensive lymph node metastasis
    Hikage, Makoto
    Fujiya, Keiichi
    Kamiya, Satoshi
    Tanizawa, Yutaka
    Bando, Etsuro
    Notsu, Akifumi
    Terashima, Masanori
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (03) : 1027 - 1037
  • [30] Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort
    Ekheden, Isabella
    Ebrahim, Fereshte
    olafsdottir, Halla
    Raaschou, Pauline
    Wettermark, Bjorn
    Henriksson, Roger
    Ye, Weimin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (07) : 1029 - 1041